REGENXBIO Announces $39M Settlement With Sarepta Resolving All Elevidys Patent Litigation

REGENXBIO has announced a $39 million settlement with Sarepta Therapeutics, resolving all patent litigation related to the Elevidys product. This settlement aims to eliminate ongoing legal disputes and allows both companies to focus on their respective business strategies. The resolution of this litigation is expected to have a positive impact on REGENXBIO's operations moving forward.